本文由小咖机器人翻译整理

期刊来源：N Engl J Med

原文链接：https://doi.org/10.1056/NEJMoa2308719

摘要内容如下：

抗淀粉样蛋白抗体已用于降低阿尔茨海默病患者的大脑β淀粉样蛋白（Aβ）负荷。在为期6个月的研究中，我们将聚焦超声应用于6个月一次的ADuCanumab输注，以暂时打开血脑屏障，目的是增强3名参与者选定脑区的淀粉样蛋白清除。如通过氟-18氟倍他滨正电子发射断层扫描所测量的，在接受聚焦超声治疗的区域中，Aβ水平的降低在数值上大于未接受聚焦超声治疗的对侧半球的同源区域。在治疗后30至180天内进行认知测试和安全性评估。（由Harry T.Mangurian，Jr.资助）基金会和西弗吉尼亚大学洛克菲勒神经科学研究所）。

英文原文如下：

Abstracts

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。

现在购买可享受最大优惠（买一年送三个月，买两年送一年），2024年2月10日起将不再享有该优惠。